All Stories

  1. Laudatio for Prof Christian Speer
  2. Effects of Hypothermia for Perinatal Asphyxia on Childhood Outcomes
  3. Challenges of Minimizing Heat Loss at Birth: A Narrative Overview of Evidence-Based Thermal Care Interventions
  4. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants
  5. Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants
  6. More about Surfactant, Oxygen, Caffeine and Chronic Lung Disease
  7. Surfactant therapy for neonatal respiratory distress syndrome in 2013
  8. Potassium canrenoate treatment in paediatric patients
  9. Surfactant therapy: past, present and future
  10. Prophylactic ranitidine treatment in critically ill children - a population pharmacokinetic study
  11. Better Neonatal Outcomes: Oxygen, Surfactant and Drug Delivery
  12. European Consensus Guidelines on the Management of Neonatal Respiratory Distress Syndrome in Preterm Infants - 2013 Update
  13. The MOMENTS Study: Improving the outcome of pregnancy and early infancy with an intervention using mentors in socially deprived areas of Belfast
  14. Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants
  15. Population pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients
  16. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates
  17. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates
  18. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants
  19. Lung Diseases: Surfactant Replacement Therapy
  20. Cochrane Review Update
  21. Lung Diseases: Problems of Steroid Treatment of Fetus and Newborn
  22. Oxygen Saturation in Immature Babies: Revisited with Updated Recommendations
  23. Mikko Hallman – A Major Translator of Basic Science into Neonatal Medicine
  24. Preface
  25. Surfactant Broadens Its Horizons
  26. Extremely Low-Dose Dexamethasone to Facilitate Extubation in Mechanically Ventilated Preterm Babies
  27. Interventions to prevent hypothermia at birth in preterm and/or low birthweight infants
  28. Development and validation of a dried blood spot–HPLC assay for the determination of metronidazole in neonatal whole blood samples
  29. Development and validation of a dried blood spot—LC–APCI–MS assay for estimation of canrenone in paediatric samples
  30. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants
  31. Useless Perinatal Therapies
  32. Editorial Note
  33. Preface
  34. A Quarter Century of Surfactant Research – From Early Neonatal Stabilisation to Long-Term Outcome
  35. Postnatal Hydrocortisone for Preventing or Treating Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review
  36. Dexamethasone Treatment after the First Week of Life for Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review
  37. Dexamethasone Treatment in the First Week of Life for Preventing Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review
  38. The Neonatal European Study of Inhaled Steroids (NEUROSIS): An EU-Funded International Randomised Controlled Trial in Preterm Infants
  39. European Consensus Guidelines on the Management of Neonatal Respiratory Distress Syndrome in Preterm Infants – 2010 Update
  40. Assessment of brain tissue injury after moderate hypothermia in neonates with hypoxic–ischaemic encephalopathy: a nested substudy of a randomised controlled trial
  41. Neonatal management and long-term sequelae
  42. Moderate Hypothermia to Treat Perinatal Asphyxial Encephalopathy
  43. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants
  44. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants
  45. Bengt Robertson (1935–2008): A Pioneer and Leader in Surfactant Research
  46. Preface
  47. Quantification of <i>Hox</i> and <i>Surfactant Protein-B</i> Transcription during Murine Lung Development
  48. The TOBY Study. Whole body hypothermia for the treatment of perinatal asphyxial encephalopathy: A randomised controlled trial
  49. Peer-mentoring for first-time mothers from areas of socio-economic disadvantage: A qualitative study within a randomised controlled trial
  50. Interventions to prevent hypothermia at birth in preterm and/or low birthweight infants
  51. Editorial Note: Sources of Neonatal Medicine
  52. Ola Didrik Saugstad – An Oxygen Radical
  53. What is the Evidence for Drug Therapy in the Prevention and Management of Bronchopulmonary Dysplasia?
  54. Preface
  55. Maternal Betamethasone and Chorioamnionitis Induce Different Collagenases during Lung Maturation in Fetal Sheep
  56. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates
  57. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants
  58. Preface
  59. European consensus guidelines on the management of neonatal respiratory distress syndrome
  60. Loop diuretics during blood transfusion for anemia in preterm infants
  61. Neonatal Rds–Surfactant
  62. Neonatal Rds-Prenatal Corticosteroids
  63. Editorial Note
  64. Editorial Note
  65. Recent Clinical Trials of Surfactant Treatment for Neonates
  66. Surfactant Replacement Therapy from 1986 to 2006: A 20-Year Success Story
  67. Evidence-based neonatal care
  68. History of Surfactant from 1980
  69. Management of Bronchopulmonary Dysplasia in Infants
  70. Recent Advances in Neonatal Medicine. An International Symposium Honoring Prof. Henry L. Halliday. Würzburg, October 7–9, 2005
  71. Recent Advances in Neonatal Medicine. An International Symposium Honoring Prof. Henry L. Halliday. Würzburg, October 7–9, 2005
  72. Modeling and Remodeling of the Lung in Neonatal Chronic Lung Disease
  73. Applications to a research ethics committee
  74. Airway proteins?surfactants
  75. Prevention strategies of chronic lung disease
  76. Editorial Note
  77. Editorial Note
  78. Preface
  79. Postnatal steroids and chronic lung disease in the newborn
  80. Use of steroids in the perinatal period1
  81. Effects of Glucocorticoids on Fetal and Neonatal Lung Development
  82. What interventions facilitate weaning from the ventilator? A review of the evidence from systematic reviews
  83. 16A Intensive care
  84. Chorioamnionitis and increased neonatal lung lavage fluid matrix metalloproteinase-9 levels: Implications for antenatal origins of chronic lung disease
  85. Corticosteroids in the prevention and management of bronchopulmonary dysplasia
  86. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants
  87. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants
  88. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants
  89. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates
  90. Preface
  91. Developmental and Clinical Aspects of Surfactant-Related Neonatal Lung Disease
  92. Airway remodelling in chronic lung disease of prematurity
  93. Preface
  94. Oxidative Stress and Increased Type-IV Collagenase Levels in Bronchoalveolar Lavage Fluid from Newborn Babies
  95. The effect of postnatal steroids on growth and development
  96. Endotracheal intubation at birth for preventing morbidity and mortality in vigorous, meconium-stained infants born at term
  97. Preface
  98. Preface
  99. A Risk-Benefit Assessment of Drugs Used for Neonatal Chronic Lung Disease
  100. The effect of early feeding on the neonatal blood glucose level at 1-hour of age
  101. Clinical Trials of Postnatal Corticosteroids: Inhaled and Systemic
  102. Current Perspectives on the Drug Treatment of Neonatal Respiratory Distress Syndrome
  103. Principles of surfactant replacement
  104. Incidence of Molecular Forms of Bile Salt-Stimulated Lipase in Preterm and Term Human Milk
  105. Molecular Forms of Bile Salt Stimulated Lipase in Human Milk
  106. Lyso-phosphatidylcholine and outcome of preterm babies with respiratory distress syndrome treated with surfactant
  107. Behavioural Adjustment in School of Very Low Birthweight Children
  108. Clinical Trials of Surfactant Replacement in Europe
  109. Treatment of severe meconium aspiration syndrome with porcine surfactant
  110. Natural vs Synthetic Surfactants in Neonatal Respiratory Distress Syndrome
  111. Where Are We Now with the Prenatal Steroids and Postnatal Surfactant
  112. Surfactant replacement therapy
  113. Preface
  114. Overview of Clinical Trials Comparing Natural and Synthetic Surfactants
  115. Has it been done before?
  116. The Effect of Epoetin Beta (Recombinant Human Erythropoietin) on the Need for Transfusion in Very-Low-Birth-Weight Infants
  117. Surfactant therapy in the newborn
  118. MIXED MCT/LCT LIPID EMULSION USE IN SICK VLBW INFANTS
  119. Total Body Water Measurement by Bioelectrical Impedance in the Extremely Low Birth Weight Infant
  120. Randomized multicentre trial of treatment with porcine natural surfactant for moderately severe neonatal respiratory distress syndrome
  121. INTERLEUKIN-6 LEVELS IN NEONATAL SEPSIS
  122. TOTAL ENERGY EXPENDITURE (TEE) IN VENTILATOR DEPENDENT EXTREMELY-LOW-BIRTHWEIGHT (ELBW) INFANTS
  123. On exogenous surfactant therapy
  124. Long term predictive value of Doppler studies in high risk fetuses
  125. The social competence of very-low-birthweight children: Teacher, peer, and self-perceptions
  126. Surfactant Replacement Therapy and the Prevalence of Acute Retinopathy of Prematurity
  127. Plasma manganese, selenium and glutathione peroxidase levels in the mother and newborn infant
  128. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: implications for nursing care
  129. The Effects of Being Born of Very-Low-Birthweight
  130. Plasma Amino Acids in Interrupted Aortic Arch and the Hypoplastic Left Heart Syndrome
  131. HANDBOOK OF NEON A TAL INTENSIVE CARE. Second Edition. By Henry L. Halliday, Garth McClure, and Mark Reid.
  132. Growth and development two years after artificial surfactant replacement at birth
  133. Controlled trial of new formulae for feeding low birth weight infants
  134. Iron Status of the Preterm Infant during the First Year of Life
  135. Results of heavy drinking in pregnancy
  136. Evaluation of Television Consultations Between a Large Neonatal Care Hospital and a Community Hospital
  137. Prediction of Neonatal Death or Need for Interhospital Transfer by Prenatal Risk Characteristics of Mother